| Literature DB >> 31337059 |
Kumar Ganesan1,2, Baojun Xu3.
Abstract
Diabetes mellitus is a multifactorial, heterogeneous metabolic disorder, causing various health complications and economic issues, which apparently impacts the human's life. Currently, commercial diabetic drugs are clinically managed for diabetic treatment that has definite side effects. Dietary polysaccharides mainly derive from natural sources, including medicinal plants, grains, fruits, vegetables, edible mushroom, and medicinal foods, and possess anti-diabetic potential. Hence, this review summarizes the effects of dietary polysaccharides on diabetes and underlying molecular mechanisms related to inflammatory factors, oxidative stress, and diabetes in various animal models. The analysis of literature and appropriate data on anti-diabetic polysaccharide from electronic databases was conducted. In vivo and in vitro trials have revealed that treatment of these polysaccharides has hypoglycemic, hypolipidemic, antioxidant, and anti-inflammatory effects, which enhance pancreatic β-cell mass and alleviates β-cell dysfunction. It enhances insulin signaling pathways through insulin receptors and activates the PI3K/Akt pathway, and eventually modulates ERK/JNK/MAPK pathway. In conclusion, dietary polysaccharides can effectively ameliorate hyperglycemia, hyperlipidemia, low-grade inflammation, and oxidative stress in type 2 diabetes mellitus (T2DM), and, thus, consumption of polysaccharides can be a valuable choice for diabetic control.Entities:
Keywords: anti-diabetic effects; dietary polysaccharides; molecular mechanisms; oxidative stress
Year: 2019 PMID: 31337059 PMCID: PMC6680889 DOI: 10.3390/molecules24142556
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Dietary polysaccharides exert favorable effects on glucose homeostasis and reduce insulin resistance. IR: insulin receptor, IRS: insulin receptor substrate, PI3K: phosphoinositide 3-kinase, AKT: serine/threonine-specific protein kinase, ROS: reactive oxygen species, RNS: reactive nitrogen species, LPO: lipid peroxidation.
In vitro and in vivo actions of dietary polysaccharides and their anti-diabetic potential.
| Source of Polysaccharides | Botanical Name/Composition | Model | Doses and Route of Administration | Negative Control | Investigation | Results | References |
|---|---|---|---|---|---|---|---|
| Mushroom |
| Wistar mice | 100 and 400 mg/kg, p.o. for 4 weeks | STZ (60 mg/kg, i.p) | FBG, Serum Insulin, OGTT, AST, ALT, BUN, CRE, LDL-C, TC, HDL-C, hepatic, renal, and pancreatic SOD, GSH-Px, CAT, and lipid peroxidation | Antioxidant and hypoglycemic effects | [ |
| Mushroom |
| Wistar rats | 10 and 100 mg/kg, p.o. for 4 weeks | STZ (40 mg/kg, i.p) | FBG and PBG | Antioxidant and hypoglycemic effects | [ |
| Mushroom | SD male rats | 500 mg and 2000 mg/kg, p.o. for 3 weeks | STZ (40 mg/kg, i.p) | FBG, PK, SOD, GSH-Px, TG, TC, BUN, UA, CRE, and urine protein levels | Anti-diabetic and anti-nephropathic activities | [ | |
| Mushroom |
| Sprague-Dawley male rats | 0.5, 1.0, and 2.0 g/kg, p.o. for 4 weeks | STZ (40 mg/kg, i.p) | FBG, PK, SOD, GSH-Px, TG, TC, BUN, UA, CRE, urine protein, NAG, and MDA | Anti-diabetic and antinephritic activities | [ |
| Mushroom |
| Male BALB/c mice and male Sprague-Dawley rats | 200 mg, 400 mg/kg, p.o. for 1-week | STZ (60 mg/kg, i.p), Alloxan monohydrate (150 mg/kg, i.p.) | Blood glucose and insulin | Hypoglycemic activity | [ |
| Mushroom |
| C57BL/6J mice | 360 mg/kg/p.o. for 8 weeks | HFD + STZ (60 mg/kg, i.p) + nicotinamide (180 mg/kg, i.p) | FBG, OGTT, IPITT, CRE, AGEs, TGF- | Anti-diabetic and renoprotective activities | [ |
| Mushroom |
| Sprague-Dawley male rats | 0.08, 0.4, and 2.0 g/kg/p.o. for 4 weeks | HFD + STZ (25 mg/kg, i.p) + nicotinamide (180 mg/kg, i.p) | Blood glucose, TC, LDL-C, insulin, PK, glycogen, SOD, MDA, GSH-Px IL-2, IL-6, IL-10, and TNF-α | Anti-diabetic and antinephritic Activities | [ |
| Mushroom |
| HepG2 cells and insulin-resistant HepG2 cells | 10, 20, 40, 80, and 160 μg/mL, for 24 and 48 h. | - | Glucose, insulin | Hypoglycemic activity | [ |
| Mushroom |
| - | 50 μL | - | α-glucosidase inhibitory activity | Anti-diabetic activity | [ |
| Mushroom |
| Male ICR mice, HepG2 | 75 and 150 mg/kg for 0, 14, and 28 days; 100 μg/mL | STZ (40 mg/kg, i.p) | Glucose, OGTT, insulin, IRS1, JNK1, PI3K, or GLUT4 | Anti-diabetic activity | [ |
| Mushroom | Male SD rats | 0.5, 1 g/kg bw | Pancreatectomy rats with 1 g dextrin/kg bw | Serum glucose, food intake, body weight, and OGTT | Anti-diabetic activity | [ | |
| Mushroom |
| Male SD rats | 1.0 and 2.0 g/kg bw, p.o. for 4 weeks | STZ (40 mg/kg, i.p) | α-glucosidase, blood glucose, SOD, GSH-Px, MDA, TC, TG, LDL-C, HDL-C, and MTT | Antioxidant, Hypoglycemic, Hypolipidemic, and Antitumor Activities | [ |
| Mushroom |
| Male SD rats | 0.5, 1.0, and 2.0 g/kg bw, p.o. for 8 weeks | STZ (35 mg/kg, i.v.) | Blood glucose, GSH, CAT, SOD, and LPO | Anti-diabetic activity | [ |
| Mushroom |
| Male SD rats | 1.0 and 2.0 g/kg bw, p.o. for 4 weeks | STZ (35 mg/kg, i.v.) | Blood glucose, GSH, CAT, SOD, LPO, TBARS, GSH-Px, and GSH-R | Anti-diabetic activity | [ |
| Mushroom |
| KK-Ay Mice | 1.0 and 2.0 g/kg bw, p.o. for 4 weeks | STZ (35 mg/kg, i.v.) | Blood glucose, AMPK, GLUT-4, Akt, and PKC | Anti-diabetic activity | [ |
| Mushroom |
| Rabbits | 100, 200, and 300 mg/kg for 4 weeks | Alloxan (120 mg/kg, p.o) | Blood glucose, ALP, γGT, ALT, AST, bilirubin, urea, BUN, CRE, Na, and K | Anti-diabetic activity | [ |
| Mushroom |
| Male Kunming mic | 900 mg/kg for 4 weeks | STZ (60 mg/kg, i.p.) | Blood glucose, body weight, organ weight, glycogen, OGTT, TC, TG, LDL-C, HDL-C, PI3K, GLUT-4, and Akt | Anti-diabetic activity | [ |
| Mushroom |
| In vitro | - | - | Pancreatic α-amylase, intestinal α-glucosidase, and ACE | Antioxidant, Hypoglycemic and Hypotensive Activities | [ |
| Mushroom |
| Male ICR mice | 0.2 g/kg for 4 weeks | STZ (150 mg/kg, i.p.) | Blood glucose, TC, TG, LDL-C, and HDL-C | Anti-diabetic activity | [ |
| Mushroom |
| In vitro, in vivo (Male ICR mice) | 200 and 400 mg/kg for 6 weeks | STZ (150 mg/kg, i.p.) | α-amylase inhibition assay, glucose uptake by yeast cells, glucose adsorption capacity, and blood glucose | Anti-diabetic activity | [ |
| Mushroom |
| KKAy mice | 1 g/kg for 6 weeks | STZ (150 mg/kg, i.p.) | Blood glucose, insulin, FBS, OGTT, TC, TG, LDL-C, HDL-C, liver glycogen | Hypolipidemic and hypoglycemic activities | [ |
| Grains | Foxtail Millet | Open-label, self-controlled clinical trial 64 subjects (27 male subjects and 37 female subjects) | 50–150 g of whole grain for week 6 and 12 | Diabetic patients | FBG, insulin, fructosamine, fasting C-peptide, TG, and TC HDL-C, LDL-C, apolipoprotein A1 and B, TNF-α, IL-6, leptin, GLP-1, blood pressure, body weight, waist circumference, and hip circumference | Anti-diabetic activity | [ |
| Vegetable, fruit, and grain | Vegetable, fruit, and grain | 48,835 post-menopausal women | A 1:1:0.5–serving/day vegetable, fruit, food grains | Diabetic patients | Serum glucose, insulin, and waist circumference | Reduced the risk of diabetes | [ |
| Whole Grain cereals | Whole grain cereals | A meta-analysis of randomized controlled trials | 50 g/day | Healthy Subjects | Serum glucose, insulin, and HbAlc | Improved the PBG and insulin homeostasis | [ |
| Grain and Sprouted grain | Grain and sprouted grain | 12 male subjects | 50 g/day | Healthy Subjects | Serum glucose, insulin, and HbAlc | Only sprouted-grain improved PBG and insulin | [ |
| Whole Grains muffins | Wheat, rice, corn, oat, and barley | 4 Male and 8 Female | 50 g/day | Healthy Subjects | Serum glucose, insulin, and HbAlc | Lowered the PBG | [ |
| Whole grains bread | Chickpea-wheat composite bread | 13 female subjects | 50 g/day | Healthy Subjects | Serum glucose, insulin, and HbAlc | Reduced PBG | [ |
| Whole grains bread | Maize | 30 male subjects | 50 g/day | Healthy Subjects | Serum glucose | Reduced PBG | [ |
| Sorghum and Wheat muffin | Sorghum and wheat flour | 10 male subjects | 50 g/day | Healthy Subjects | Serum glucose, insulin | Improved the PBG and insulin | [ |
| Whole rye bread | Whole rye with white wheat bread | 6 males and 9 females | 50 g/day | Healthy Subjects | Serum glucose, insulin | Improved the insulin response | [ |
| Oat | Oat | A meta-analysis of randomized controlled trials | 50 g/day | Healthy Subjects | Serum glucose, insulin | Improved glucose and insulin response | [ |
| Oat and beta-glucan | Oat and beta-glucan | A meta-analysis of randomized controlled trials | - | Healthy Subjects | Serum glucose, HbA1c, and insulin | Improved glucose and insulin and HbA1c response | [ |
| Whole grain rye with starch | Whole grain rye flour and rye kernels bread | 21 subjects | 50 g/day | Healthy Subjects | Serum glucose, OGTT, insulin, PYY, FFA, and IL-6 | Improved cardiometabolic variables and glucose | [ |
| Whole grain oats | Whole grain oats | A meta-analysis of randomized controlled trials | - | Healthy Subjects | Serum glucose, OGTT, insulin, and TC | Cholesterol-lowering and anti-diabetic effects | [ |
| Whole-grain rye and wheat bread | Whole-grain rye porridges and refined wheat bread | 21 subjects | 40, 55 g/day | Healthy Subjects | Serum glucose, postprandial plasma amino acids and short chain fatty acids | Suppressed appetite and improved glucose metabolism. | [ |
| Canola oil-enriched bread supplement | Canola oil-enriched bread | 141 subjects | 31 g/day | Diabetic patients | HbA1c, blood pressure, Framingham CVD risk score, and reactive hyperemia index ratio | Improved glycemic control in T2DM | [ |
| Grains | Monascus-fermented grains | Male SD rats | 300 mg/kg bw. For 16 weeks | High-fructose (60%, | OGTT, Insulin, insulin sensitivity index, TBARS, SOD, CAT, and GPx | Anti-diabetic effect by improving insulin resistance and hepatic antioxidant enzymes. | [ |
| Whole grains and legumes | Whole grains and legumes | 39 males, 146 females | 30–70 g for 16 weeks | Diabetic patients | BMI, waist and hip ratio, TC, TG, LDL-C, HDL-C, FBS, insulin FFA, Plasma apolipoprotein A-V, and CRP | Anti-diabetic effects | [ |
| DASH diet | fruits, vegetables, whole grains, low-fat dairy products, low in saturated fats, cholesterol, refined grains, and sweets | 52 pregnant women | 40 g for 4 weeks | Gestational Diabetic patients | Length, weight, and head circumference of infants | Improved gestational diabetes mellitus | [ |
| Whole grains | Cereal, bread, rice, pasta, and muffin | 11 subjects | 6–10 servings/day for 6 weeks | Diabetic/obese patients | Insulin, blood glucose, and OGTT | Reduce the risk of T2DM and heart disease. | [ |
| Vegetables | Okra ( | Male C57BL/6 mice | 50 mg/kg, p.o for 10 days | STZ (45 mg/kg, i.p.) | blood glucose, OGTT | Hypoglycemic effect | [ |
| Vegetables | Red pepper and soybeans | Male SD rats | 5% powder supplement | STZ (45 mg/kg, i.p.) | FBS, OGTT, body weight, visceral fat, and serum leptin | Improves glucose homeostasis by reducing insulin resistance | [ |
| Fruits and vegetables | Fruits and vegetables | 550 children and adolescents | 257, 227 g/day for 30 days | Diabetic patients | FBS, insulin, and HbA1c | Anti-diabetic effect | [ |
| Vegetables | Purple carrots and purple potatoes | Obese Zucker rats | Purple carrot and potatoes supplemented a high-fat diet for 8 weeks. | - | Intraperitoneal glucose and insulin tolerance test and invasive hemodynamic tests | Purple vegetables improve insulin resistance and hypertension | [ |
| Apricot Lychee |
| In vitro | - | - | α-glycosidase, aldose reductase, and antioxidant activity | Anti-diabetic effects | [ |
| Blueberry |
| ||||||
| Plum |
| ||||||
| Kiwi |
| ||||||
| Lemon pulp |
| ||||||
| Lemon peel |
| ||||||
| Pear |
| ||||||
| Wolfberry |
| ||||||
| Watermelon |
| ||||||
| Lettuce |
| In vitro | - | - | α-glycosidase, aldose reductase, and antioxidant activity | Anti-diabetic effects | [ |
| Cucumber |
| ||||||
| Red onion |
| ||||||
| Bitter gourd |
| ||||||
| Eggplant |
| ||||||
| Celery |
| ||||||
| Kelp |
| ||||||
| Wax gourd |
| ||||||
| Garlic |
| ||||||
| Tomato |
| ||||||
| Vegetables |
| SD rats | 50 mg/kg, p.o for 10 days | STZ (45 mg/kg, i.p.) | FBS, insulin, and HbA1c | Anti-diabetic effects | [ |
Abbreviations: ACE-angiotensin converting enzyme; AGEs-advanced glycation end products; Akt-serine/threonine-specific protein kinase; ALP-alkaline phosphatase; ALT-alanine transaminase; AST-aspartate transaminase; BUN-blood urea nitrogen; CAT-catalase; CRE-creatinine; CRP-C-reactive protein; FBG-fasting blood glucose; FFA-free fatty acids; GLP-1-glucagon-like peptide-1; GLUT4-glucose transporter 4; GSH-Px-glutathione peroxidase; GSH-R-glutathione reductase; HbA1c-glycated hemoglobin; HDL-C-high density lipoprotein–C; HepG2-human liver cancer cell line; HFD-high-fat diet; IL-interleukin; IL-6-interleukin-6; IPITT-intraperitoneal insulin tolerance test; IRS1-insulin receptor substrate 1; JNK-c-Jun N-terminal kinases; K-potassium; LDL-C-low density lipoprotein–C; LPO-lipid peroxidation; MDA-malondialdehyde; MTT-3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium; Na-sodium; NAG-n-acetyl-β-d-glucosaminidase; OGTT-oral glucose tolerance test; PBG-postprandial glucose; PI3K-phosphoinositide 3-kinases; PK-pyruvate kinase; PKC-protein kinase C; PYY-peptide tyrosine tyrosine hormone; SD-Sprague-Dawley; SOD-superoxide dismutase; TC-total cholesterol; T2DM-type 2 diabetes; TG-triglycerides; TGF-β1-transforming growth factor-β1; TNF-α-tumor necrosis factor-α; UA-uric acid; γGT-gamma-glutamyltransferase; i.v-intravenous; i.p-intraperitoneal; b.w-body weight; DASH-dietary approaches to stop hypertension.
Anti-cholesterolemic and anti-triglyceridemic effects of dietary polysaccharides.
| Sources of Polysaccharides | Monosaccharide Units/Active Compounds | Effects on Metabolism | Molecular Mechanisms | Results | References |
|---|---|---|---|---|---|
|
| Rhamnose, arabinose, xylose, mannose, glucose, and galactose | Triglyceride metabolism | ↑ATGL, ↑PPAR-α, ↑PPARɣ coactivator-1 α, ↓FAS, ↓HMG-CoA reductase | Anti-hyperlipidemic effects | [ |
| Sorbin, glucose, fructose, and glucitol | Triglyceride metabolism | ↑p-AMPK, ↑ATGL, ↑CAPT1, ↑p-ACC, ↓FAS, | Anti-hyperlipidemic effects | [ | |
|
| Rhamnose, arabinose, xylose, mannose, glucose, galactose, and galacturonic acid | Triglyceride metabolism | ↑p-AMPK, ↑p-ACC, ↑ATGL, ↑CAPT1, ↓FAS | Anti-hyperlipidemic effects | [ |
|
| Rhamnose, glucuronic acid, arabinose, fucose, xylose, and glucose | Cholesterol metabolism | ↓SREBP-2, ↓HMG-CoA reductase | Cholesterol-lowering effects | [ |
| Xylose, rhamnose, mannose, galactose, arabinose, and glucose | Triglyceride and cholesterol metabolism | ↑PPAR-α, ↑PPARɣ coactivator-1 α, ↓SREBP-1c | Anti-hyperlipidemic effects | [ | |
|
| Arabinose, mannose, glucose, and galactose | Cholesterol metabolism | ↓HMG-CoA reductase | Cholesterol-lowering effects | [ |
|
| α- and | Cholesterol metabolism | ↓HMG-CoA reductase | Cholesterol-lowering effects | [ |
|
| Sulfated polysaccharide with fucose | Triglycerides and cholesterol metabolism | ↓FAS, ↓ACC, ↓SREBP -1c, ↓SREBP-2, ↓HMG-CoA reductase | Triglyceride and Cholesterol-lowering effects | [ |
|
| Rhamnose, arabinose, xylose, mannose, glucose, galactose, and galacturonic acid | Triglyceride and cholesterol metabolism | ↑p-AMPK, ↑PPARɣ coactivator-1 α, ↑p-ACC, ↓FAS, ↓SREBP-1c | Anti-hyperlipidemic effects | [ |
| Rhamnose, mannose, and galactose | Triglyceride metabolism | ↑p-AMPK, ↑p-ACC | Anti-hyperlipidemic effects | [ | |
|
| Galactose, arabinose, and glucose | Triglyceride and cholesterol metabolism | ↓SREBP-1c, ↓SREBP-2, ↓FAS | Anti-hyperlipidemic effects | [ |
| α- | Cholesterol metabolism | ↑LDL receptor, ↓HMG-CoA reductase | Cholesterol-lowering effects | [ | |
|
| Galactose, mannose, fucose, rhamnose, arabinose, xylose, glucose, and alduronic acids | Cholesterol metabolism | ↑LDL receptor, ↑PPAR-α | Cholesterol-lowering effects | [ |
Abbreviations: ATGL-adipose triglyceride lipase; PPAR-α-peroxisome proliferator-activated receptor alpha; FAS-fatty acid synthase; HMG-CoA reductase-3-hydroxy-3-methylglutaryl-CoA reductase; p-AMPK-phosphorylated serine/threonine protein kinase; CAPT1-carnitine palmitoyltransferase-1; p-ACC-phosphorylated acetyl-CoA carboxylase; SREBP-2-sterol regulatory element binding protein-2; SREBP-1c-sterol regulatory element binding protein-1c, ↑ increase; ↓ decrease.
Figure 2Schematic representation of the action of dietary polysaccharides on the insulin signaling pathway. Dietary polysaccharides elevate the cascade signaling of IRS/PI3K/AKT/GLUT4 and inhibit GSK3/GS, eventually stimulating the synthesis of glycogen. Akt is a main mediator to activate ERK/MAPK pathways and stimulate various physiological and biochemical mechanisms, including cell differentiation, proliferation, apoptosis, and cell endurance. IRS: insulin receptor substrate, PI3K: phosphoinositide 3-kinase, PDK1/2: Phosphoinositide-dependent protein kinase 1 and 2, AKT: serine/threonine-specific protein kinase, GSK-3: glycogen synthase kinase-3, GS: glycogen synthase, GLUT4: glucose transporter type 4, ERK: extracellular-signal-regulated kinase, MAPK: mitogen-activated protein kinase.